Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study.
Real-world data compares two common medications for fatty liver disease in practical clinical settings, informing treatment choices for this growing health problem.
Real-world multicenter propensity-matched analysis compares semaglutide vs SGLT2 inhibitors for MASLD (metabolic dysfunction-associated steatotic liver disease), an increasingly prevalent condition in cardiometabolic populations. T7 watchlist match; provides practical head-to-head comparative effectiveness data for clinicians.
What the study was
- Study design
- Multicenter propensity-matched retrospective real-world study
- Population
- Patients with MASLD initiating semaglutide or SGLT2 inhibitors in multiple centers
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Endocrine Practice
Why it surfaced
Clinically useful head-to-head comparison in MASLD. Retrospective propensity-matched design, abstract only. Score 5.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.